Abstract: A system and a method is provided for assessing motion of a biological tissue of a subject including one or more superficial biological layers and a targeted biological layer. An optical perturbation is introduced within the one or more superficial biological layers but not within the targeted biological layer. A set of optical signal data is acquired preceding, during, or following the optical perturbation and, using the set of optical signal data, a set of optical characteristics is determined that is representative of light transiting the biological layers. Using the set of optical characteristics and a model of the biological layers, a target optical signal consistent with a target biological layer is separated and a movement of the desired biological tissue is determined using the target optical signal.
Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
Type:
Grant
Filed:
November 22, 2021
Date of Patent:
January 23, 2024
Assignees:
The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.
Type:
Grant
Filed:
March 5, 2020
Date of Patent:
January 23, 2024
Assignees:
Children's Medical Center Corporation, The General Hospital Corporation
Inventors:
Ross Cheloha, Hidde L. Ploegh, Thomas J. Gardella
Abstract: A method for evaluating gastric and upper small intestine motility and emptying in a gastrointestinal tract of a subject using magnetic resonance imaging includes administering a contrast agent to the subject; acquiring, using an MRI system, a set of MR data from the subject using a three-dimensional volumetric pulse sequence. The volumetric pulse sequence has a temporal resolution and a spatial resolution configured to facilitate measurement of volumetric and motility parameters. The method further includes reconstructing a set of images using the set of MR data, segmenting each image in the set of images to isolate a region of interest in the gastrointestinal tract of the subject, determining at least one volumetric and motility parameter based on the set of segmented images, and generating a report indicating the at least one volumetric or motility parameter.
Type:
Grant
Filed:
May 11, 2020
Date of Patent:
January 23, 2024
Assignee:
The General Hospital Corporation
Inventors:
Braden Kuo, Christopher Nguyen, Roberta Sclocco, Vitaly Napadow
Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.
Type:
Application
Filed:
June 30, 2023
Publication date:
January 18, 2024
Applicant:
The General Hospital Corporation
Inventors:
Dilip Paithankar, Richard Dean Blomgren, Richard Rox Anderson, William A. Farinelli, Apostolos G. Doukas
Abstract: Described here are systems and methods for producing images with a magnetic resonance imaging (“MRI”) system using a high-resolution, motion-robust, artifact-free segmented echo planar imaging (“EPI”) technique. In particular, a fast low angle excitation echo planar imaging technique (“FLEET”) using variable flip angle (“VFA”) radio frequency (“RF”) excitation pulses that are recursively designed to have a flat magnitude and phase profile across a slice for a range of different flip angles by accounting for longitudinal magnetization remaining after each preceding RF pulse is applied.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
January 16, 2024
Assignee:
The General Hospital Corporation
Inventors:
Avery J. L. Berman, Jonathan R. Polimeni, William A. Grissom, Kawin Setsompop, Thomas Witzel
Abstract: An apparatus, including: a probe to interface with a surface of a tissue; a light source optically coupled to the probe, the light source directing light of at least 1000 nm into the tissue; a detector optically coupled to the probe, the detector to detect light based on scattering of light from the light source in the tissue, and the detector having a light sensitivity in a range of at least 1000 nm; a processor coupled to the detector, the processor to: receive a signal from the detector corresponding to the detected light from the light source, and determine a blood flow measurement from the region of interest using diffuse correlation spectroscopy based on the signal.
Type:
Grant
Filed:
February 18, 2019
Date of Patent:
January 16, 2024
Assignees:
The General Hospital Corporation, Massachusetts Institute of Technology
Inventors:
Maria Angela Franceschini, Stefan Carp, Davide Tamborini, David Boas, Bruce Rosen, Megan Blackwell, Oleg Shatrovoy
Abstract: Higher quality diffusion metrics and/or diffusion-weighted images are generated from lower quality input diffusion-weighted images using a suitably trained neural network (or other machine learning algorithm). High-fidelity scalar and orientational diffusion metrics can be extracted using a theoretical minimum of a single non-diffusion-weighted image and six diffusion-weighted images, achieved with data-driven supervised deep learning. As an example, a deep convolutional neural network (“CNN”) is used to map the input non-diffusion-weighted image and diffusion-weighted images sampled along six optimized diffusion-encoding directions to the residuals between the input and output high-quality non-diffusion-weighted image and diffusion-weighted images, which enables residual learning to boost the performance of CNN and full tensor fitting to generate any scalar and orientational diffusion metrics.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
January 16, 2024
Assignee:
The General Hospital Corporation
Inventors:
Qiyuan Tian, Susie Yi Huang, Berkin Bilgic
Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
Type:
Application
Filed:
July 13, 2022
Publication date:
January 11, 2024
Applicant:
THE GENERAL HOSPITAL CORPORATION
Inventors:
Nicola ACETO, Daniel Arie HABER, Shyamala MAHESWARAN
Abstract: Apparatus and method can be provided for obtaining at least one anatomical sample. For example, it is possible to provide and insert a housing into a body or provided on a hydrated anatomical structure. Further, with a source, it is possible to emit an electromagnetic radiation which causes at least the anatomical sample(s) to attach to at least one portion of the housing. A compound can be provided on a surface of the housing, and the source provides the radiation to the compound and changes properties thereof to be adhesive. The source can provide the radiation to the housing, and can change properties of a surface thereof to be adhesive. A component can be provided on a surface of the anatomical structure, and the source provides the radiation to the compound and changes properties thereof to be adhesive.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
January 9, 2024
Assignee:
The General Hospital Corporation
Inventors:
Guillermo J. Tearney, Joseph Gardecki, Chia-Pin Liang
Abstract: Described herein are methods for diagnosing and monitoring subjects with diseases associated with aberrant splicing, based upon detecting properly spliced isoforms and mis-spliced isoforms in a urine sample from the subject.
Type:
Grant
Filed:
July 21, 2017
Date of Patent:
January 9, 2024
Assignee:
The General Hospital Corporation
Inventors:
Thurman Wheeler, Xandra O. Breakefield, Leonora Balaj
Abstract: The invention encompasses water-forming NADH and NADPH oxidases and the use of these enzymes to treat mammalian diseases or conditions associated with an elevated NADH/NAD+ ratio or NADPH/NADP+ ratio. Such pathologies include disorders caused by one or more defects in the mitochondrial respiratory chain, glucose metabolism disorders, cancers associated with reductive stress, and aging. The invention also provides a research tool for investigating the effect of exogenous water-forming NADH or NADPH oxidases on the metabolism of a mammalian cell, such as a human cell, and for elucidating the role of respiratory chain proteins in mitochondrial disorders.
Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 4, 2024
Applicants:
Seagen Inc., The General Hospital Corporation
Inventors:
David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 4, 2024
Applicants:
Seagen Inc., The General Hospital Corporation
Inventors:
David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Abstract: Systems and methods for monitoring a subject under, or suspected to be under, the influence of one or more drugs are provided. In one aspect, a method comprises controlling one or more sensors of a monitoring device to acquire physiological signals from a subject suspected to be under the influence of one or more drugs, and assembling a set of physiological data using the acquired physiological signals. The method also includes generating, using a processor of the monitoring device, physiological markers characteristic of the influence of the one or more drugs by analyzing the set of physiological data, and correlating the physiological markers with a drug profile characterizing the one or more drugs affecting the subject. The method further includes proving to a user a report indicating the drug profile characterizing the one or more drugs affecting the subject.
Type:
Grant
Filed:
October 4, 2018
Date of Patent:
January 2, 2024
Assignee:
The General Hospital Corporation
Inventors:
Jacob A Donoghue, Kathleen J. Koenigs, Patrick L Purdon, Emery N. Brown
Abstract: The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
Abstract: Disclosed herein is a nanosensor of miRNA activity in a target cell, and methods of use, for detection and diagnostic applications. The nanosensor comprises a delivery particle comprising an iron oxide crystal coated with a polymer, and a sensor oligonucleotide covalently attached to the polymer. The sensor oligonucleotide comprises a seed region, comprising a nucleic acid sequence that is completely complementary to the target miRNA and comprises a cleavage site which can be engaged and cleaved by the target miRNA. The senor oligonucleotide also comprises two non-seed regions that each flank the seed region and are each comprised of a nucleic acid sequence that is complementary to the target miRNA to promote hybridization of the sensor oligonucleotide to the target miRNA, and members of a quencher-fluorophore pair. The quencher fluorophore pair members respectively flank the cleavage site and are separated by a distance that permits significant quenching of emitted fluorescent signal.
Abstract: The present invention relates to methods for making wear and oxidation resistant polymeric materials by high temperature melting. The invention also provides methods of making medical implants containing cross-linked antioxidant-containing tough and ductile polymers and materials used therewith also are provided.
Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
Type:
Grant
Filed:
January 8, 2020
Date of Patent:
December 26, 2023
Assignees:
Whitehead Institute for Biomedical Research, The General Hospital Corporation
Inventors:
Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher